Mivavotinib for relapsed/refractory B-cell lymphoma
by Impact Journals LLCKaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population). Credit: 2023 Gordon et al.In a new research paper published inOnco
Updated on: January 02,2024
10

Mivavotinib for relapsed/refractory B-cell lymphoma
by Impact Journals LLCKaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population). Credit: 2023 Gordon et al.In a new research paper published inOnco
Updated on:January 02,2024
10
